SIHNV Composition Plan definition

SIHNV Composition Plan means this composition plan (ontwerp van een akkoord). "SIHNV Contingent Payment Undertakings" means the:
SIHNV Composition Plan means the draft composition plan (in Dutch: “ontwerpakkoord”) originally dated 15 February 2021, substantially in the form as submitted by SIHNV together with its application for the SoP Proceedings dated 15 February 2021 and as may be amended until the court hearing scheduled pursuant to Section 255(1)(2°) of the Dutch Bankruptcy Act (in Dutch: “Faillissementswet”);
SIHNV Composition Plan means the composition plan (ontwerp van akkoord) pursuant to Section 252 of the Dutch Bankruptcy Act (Faillissementswet), to be as offered by SIHNV to its creditors (as may be amended) and as accepted by them the committee of representation (commissie van vertegenwoordiging) in the court hearing scheduled pursuantto Section 255(1)(2o) of the Dutch Bankruptcy Act and confirmed (gehomologeerd) by the competent court in a final and unappealable judgment (in kracht van gewijsde);

Examples of SIHNV Composition Plan in a sentence

  • This Schedule sets out the principles for the valuation of the Claims of each Distribution Creditor, which shall be their Claim Value for the purposes of this SIHNV Composition Plan.

  • One of these reflects the fact that the Proposal is being made in conjunction with, and is dependent on the success of, a proposal by SIHNV for the settlement and compromise of its litigation and financial liabilities in accordance with the terms of the SIHNV Composition Plan.

  • There is no subsisting default in the redemption of preference shares issued by the Company or in payment of dividend due on any preference shares issued by the Company, in the past.

  • Without the Financial Restructuring, it is unlikely that SIHNV would have been in the financial position to offer this SIHNV Composition Plan and the Distribution Creditors would not have been able to receive the same (if any) recovery on their Claims against SIHNV.

  • It is essential to note, however, that this Proposal is inter-conditional with, and dependent on the success of, a proposal by SIHNV for the settlement and compromise of its litigation and financial liabilities in accordance with the terms of the SIHNV Composition Plan.

  • SIHNV believes that this SIHNV Composition Plan represents the best achievable settlement offer to its creditors.The claims of the Distribution Creditors have been valued in accordance with the Valuation Principles.

  • Accordingly, the rights of the Other Unsecured Creditors will be preserved under this SIHNV Composition Plan.

  • First of all, it is important to emphasise that this SIHNV Composition Plan is offered to creditors, rather than (current) shareholders of SIHNV.

  • BUSINESS CREDIT APPLICATIONThis application plus Business Profile, Credit Card Authorization, Terms & Conditions (2) years' business financial statements.

  • Finally, it would cause their Claim Values to change over time, which would complicate the calculation of the settlement distributions offered pursuant to this SIHNV Composition Plan (which is expected to occur over time as well, rather than at a single interval).1.9 Therefore, with a view to efficiency and consistency, the accrual of statutory interest is not taken into account for the Claim Values of the SIHNV MPC Relevant Claims.

Related to SIHNV Composition Plan

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Licensed Compound means [***].

  • Valid write-in candidate means a candidate who has qualified as a write-in

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Development Candidate means a Collaboration Compound designated by Biogen Idec as a Development Candidate in accordance with Section 2.6.

  • Step therapy protocol means a protocol or program that establishes the specific

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Investigational Medicinal Product means the study drug or control material as defined in the Protocol.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Edible cannabis product means cannabis product that is intended to be used, in whole or in part, for human consumption, including, but not limited to, chewing gum, but excluding products set forth in Division 15 (commencing with Section 32501) of the Food and Agricultural Code. An edible cannabis product is not considered food, as defined by Section 109935 of the Health and Safety Code, or a drug, as defined by Section 109925 of the Health and Safety Code.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Diagnostic source assembly means the tube housing assembly with a beam-limiting device attached.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Assistive technology device means any item, piece of equipment, or product system that is used to increase, maintain, or improve the functional capacities of a child with a disability.

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, or Pivotal Study, as applicable; but excluding any Post-Approval Studies.

  • Manufacturing Technology means any and all patents, patent applications, Know-How, and all intellectual property rights associated therewith, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno- associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.

  • Development Plan has the meaning set forth in Section 3.2.

  • Development Plans means a coherent set of operations defined and financed exclusively by the OCTs in the framework of their own policies and strategies of development, and those agreed upon between an OCT and the Member State to which it is linked;

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • in vitro diagnostic medical device means any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment, software or system, whether used alone or in combination, intended by the manufacturer to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information:

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.